文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

宽松血糖控制策略对重症2型糖尿病患者的效应:多中心、平行组、开放标签随机临床试验

The Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A Multicenter, Parallel-Group, Open-Label Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论对重症2型糖尿病患者,宽松血糖目标(180–252 mg/dl)较标准目标(108–180 mg/dl)减少低血糖发生,但未改善以患者为中心的结局。

该多中心、平行组、开放标签随机临床试验纳入419例预期在ICU停留至少3天的成人2型糖尿病患者。干预组在血糖>252 mg/dl时启动静脉胰岛素并滴定至180–252 mg/dl,对照组在血糖>180 mg/dl时启动并滴定至108–180 mg/dl。至第28天,干预组低血糖发生率5%(10/210)显著低于对照组18%(38/209)(发生率比0.21,95%CI 0.09–0.49;P<0.001);干预组日均、最低、最高血糖更高,血糖变异性和相对低血糖更少(所有比较P<0.001)。至第90天,干预组死亡29.5%(62/210),对照组24.9%(52/209),绝对差异4.6个百分点(95%CI -3.9%至13.2%;P=0.29)。

要点

  • 重症2型糖尿病患者宽松血糖目标(180–252 mg/dl,血糖>252 mg/dl启动胰岛素)较标准目标(108–180 mg/dl,>180 mg/dl启动)减少低血糖:5%(10/210)vs 18%(38/209),发生率比0.21(95%CI 0.09–0.49),P<0.001。
  • 宽松策略组日均、最低、最高血糖更高,血糖变异性和相对低血糖更少(所有比较P<0.001)。
  • 第90天死亡率宽松组29.5%(62/210)vs 标准组24.9%(52/209),绝对差异4.6个百分点(95%CI -3.9%至13.2%),P=0.29,未达统计学显著。
  • 作者结论:宽松血糖目标方法减少低血糖发生率,但未改善以患者为中心的结局。

适用人群与场景

  • 成人2型糖尿病患者,预期在ICU停留至少连续3天。

诊断标准与关键阈值

  • 干预组:血糖>252 mg/dl时启动静脉胰岛素,滴定至目标范围180–252 mg/dl。
  • 对照组:血糖>180 mg/dl时启动静脉胰岛素,滴定至目标范围108–180 mg/dl。

处置流程与药物剂量

  • 干预组:血糖>252 mg/dl时启动静脉胰岛素,滴定至目标范围180–252 mg/dl。
  • 对照组:血糖>180 mg/dl时启动静脉胰岛素,滴定至目标范围108–180 mg/dl。

红旗征与不能漏的情况

  • 低血糖(<72 mg/dl)为研究主要终点事件,干预组发生率5%(10/210),对照组18%(38/209)。

研究设计与关键结果

  • 研究类型:多中心、平行组、开放标签随机临床试验;样本量419例(干预组210例,对照组209例)。
  • 主要终点:至第28天至少发生一次低血糖(<72 mg/dl)者干预组10/210(5%),对照组38/209(18%),发生率比0.21(95%CI 0.09–0.49),P<0.001。
  • 次要终点:干预组日均、最低、最高血糖更高,血糖变异性更小,相对低血糖更少(所有比较P<0.001)。
  • 第90天死亡:干预组62/210(29.5%),对照组52/209(24.9%),绝对差异4.6个百分点(95%CI -3.9%至13.2%),P=0.29。

证据类型、等级与局限

  • 证据类型:多中心、平行组、开放标签随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于预期ICU停留至少3天的成人2型糖尿病患者,采用宽松血糖目标(180–252 mg/dl,血糖>252 mg/dl启动胰岛素)可减少低血糖发生,但未改善以患者为中心的结局(死亡率差异无统计学意义)。

指南或共识出处

  • 临床试验注册:澳大利亚新西兰临床试验注册处(ACTRN 12616001135404)。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Blood glucose concentrations affect outcomes in critically ill patients, but the optimal target blood glucose range in those with type 2 diabetes is unknown. Objectives: To evaluate the effects of a "liberal" approach to targeted blood glucose range during ICU admission. Methods: This mutlicenter, parallel-group, open-label randomized clinical trial included 419 adult patients with type 2 diabetes expected to be in the ICU on at least three consecutive days. In the intervention group intravenous insulin was commenced at a blood glucose >252 mg/dl and titrated to a target range of 180-252 mg/dl. In the comparator group insulin was commenced at a blood glucose >180 mg/dl and titrated to a target range of 108-180 mg/dl. The primary outcome was incident hypoglycemia (<72 mg/dl). Secondary outcomes included glucose metrics and clinical outcomes. Measurements and Main Results: By Day 28, at least one episode of hypoglycemia occurred in 10 of 210 (5%) patients assigned the intervention and 38 of 209 (18%) patients assigned the comparator (incident rate ratio, 0.21 [95% confidence interval (CI), 0.09 to 0.49]; P < 0.001). Those assigned the intervention had greater blood glucose concentrations (daily mean, minimum, maximum), less glucose variability, and less relative hypoglycemia (P < 0.001 for all comparisons). By Day 90, 62 of 210 (29.5%) in the intervention and 52 of 209 (24.9%) in the comparator group had died (absolute difference, 4.6 percentage points [95% CI, -3.9% to 13.2%]; P = 0.29). Conclusions: A liberal approach to blood glucose targets reduced incident hypoglycemia but did not improve patient-centered outcomes. Clinical trial registered with Australian New Zealand Clinical Trials Registry (ACTRN 12616001135404).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Poole AP, Finnis ME, Anstey J, et al. The Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A Multicenter, Parallel-Group, Open-Label Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 35608484. doi:10.1164/rccm.202202-0329OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。